Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study ...

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not be ...

AZ and Amgen tried and failed to develop tezepelumab as a therapy for atopic dermatitis, chalking up one failed phase 3 trial in 2017, but have continued to develop the drug for other indications ...

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83. AstraZeneca’s senior director in oncology data science outlined how the ...

Patients cited many benefits of multidisciplinary CRSwNP care, including personalized treatment and more therapeutic options. “Patients with [chronic rhinosinusitis with nasal polyps (CRSwNP)] may be ...

Silent rhinovirus infection was associated with increased Th2 inflammation levels in the control group and reduced Th2 inflammation levels in the CRSwNP group. Silent rhinovirus (RV) infection is ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Xtrackers S&P 500 Swap UCITS ETF - 1C USD ACC 23% SPDR S&P 500 UCITS ETF - USD DIS 23% ...

The management framework of CRSwNP substantially shifted with the introduction of biological agents. 1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic ...